Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Organizational Principles of Biological Systems.

Biology·2026
Same author

Unveiling the influence of CAR-negative T-cells: enhancing efficacy and ensuring safety in CAR-T therapies.

Journal of translational medicine·2025
Same author

Dual targeting of BCMA and SLAMF7 with the CARtein system: chimeric antigen receptors with intein-mediated splicing elicit specific T cell activation against multiple myeloma.

Frontiers in immunology·2025
Same author

Discordant CAR-T cell signaling: implications of divergence from physiological T cell activation.

Journal of translational medicine·2025
Same author

Proteomic analysis in the brain and liver of sea bream (Sparus aurata) exposed to the antibiotics ciprofloxacin, sulfadiazine, and trimethoprim.

Environmental pollution (Barking, Essex : 1987)·2024
Same author

Development and Validation of a Highly Sensitive Multiplex Immunoassay for SARS-CoV-2 Humoral Response Monitorization: A Study of the Antibody Response in COVID-19 Patients with Different Clinical Profiles during the First and Second Waves in Cadiz, Spain.

Microorganisms·2023

相关实验视频

Updated: Jun 26, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

54.0K

基于蛋白质的模块化仿制抗原受体平台,用于特定的CD19/CD20共同向.

Pablo Gonzalez-Garcia1,2, Noelia Moares1,2, Wenjie Yi-He1,2

  • 1Departmento de Biomedicina, Biotecnología y Salud Publica, Facultad de Medicina, Universidad de Cadiz, Spain.

Molecular oncology
|October 14, 2025
PubMed
概括

CARtein是一种新的模块化仿制抗原受体 (CAR) 平台,有效向CD19和CD20等多个抗原. 这种创新方法增强了T细胞激活,解决了B细胞恶性瘤治疗的挑战.

关键词:
急性淋巴细胞白血病 (ALL)嵌合式抗原受体 (CAR) 是一种免疫疗法 免疫疗法没有任何的意义,没有任何意义.模块化的汽车汽车.非霍奇金淋巴瘤 (NHL) 是一种非霍奇金淋巴瘤.

更多相关视频

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.9K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.3K

相关实验视频

Last Updated: Jun 26, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

54.0K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.9K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.3K

科学领域:

  • 免疫学 免疫学 免疫学
  • 在瘤学瘤学.
  • 生物技术是生物技术.

背景情况:

  • 化学抗原受体 (CAR) T细胞疗法已经改变了B细胞恶性瘤治疗.
  • 抗原逃逸和瘤异质性等挑战限制了CAR T细胞的疗效.
  • 模块化CAR提供了一种策略,通过针对多个抗原来克服这些局限性.

研究的目的:

  • 介绍CARtein,一个新的模块化CAR平台,利用互动.
  • 为了使CD19和CD20抗原的同时向,使用通用CAR骨干.
  • 建立一个通用的多抗原向系统的基础.

主要方法:

  • 开发一个具有通用CAR信号骨干和scFv-intein识别合作伙伴的CARtein平台.
  • 使用CD19和/或CD20表达Raji和K562细胞的CARtein功能验证.
  • 通过NFAT和NFκB促进剂活性和CD69表达的T细胞激活的评估.

主要成果:

  • 在CARtein系统成功地产生了完全活跃的CAR.
  • 当向表达CD19和/或CD20的细胞时,观察到显著的T细胞激活.
  • 通过scFv-intein合作伙伴与CAR骨干的共价结合来证明特定的激活.

结论:

  • CARtein提供了一个新的模块化CAR平台,用于B细胞恶性瘤中的多抗原向.
  • 该系统使用相互介导的共价结合来实现精确的CAR激活.
  • 这种方法有望克服抗原逃逸并改善CAR T细胞治疗结果.